Aryeh Fischer

Aryeh Fischer

Auto-generated profile, based on publicly available information

Aryeh Fischer

Lung Fibrosis—Clinical Development Lead, Bristol Myers Squibb , Lawrenceville, NJ

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2015 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AFAryeh Fischer
Aryeh Fischer
KAKaterina M. Antoniou
Katerina M. Antoniou
KBKevin K. Brown
Kevin K. Brown
JCJacques Cadranel
Jacques Cadranel
TCTamera J. Corte
Tamera J. Corte
VCVincent Cottin
Vincent Cottin
Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack of consensus over nomenclature and classification limits the ability to conduct prospective studies of a uniform cohort.The “European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease” was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity.The task force proposes the term “interstitial pneumonia with autoimmune features” (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features.A designation of IPAF should be used to identify individuals with IIP and features suggestive of, but not definitive for, a CTD. With IPAF, a sound platform has been provided from which to launch the requisite future research investigations of a more uniform cohort.

2 August 2019 in Current Medical Research and Opinion
Verified
Journal Article
Open access
MWMarlies S. Wijsenbeek
Marlies S. Wijsenbeek
MKMichael Kreuter
Michael Kreuter
AOAmy Olson
Amy Olson
AFAryeh Fischer
Aryeh Fischer
Elisabeth BendstrupElisabeth Bendstrup
Elisabeth Bendstrup
Vincent CottinVincent Cottin
Vincent Cottin
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May–June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18–32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61–80 months. Drug treatment was given to 50–75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50–75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18–32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.

1 October 2016 in Respiratory Medicine
Verified
Journal Article
Closed access
SCSandra Chartrand
Sandra Chartrand
JSJeffrey J. Swigris
Jeffrey J. Swigris
LSLina Stanchev
Lina Stanchev
JLJoyce S. Lee
Joyce S. Lee
KBKevin K. Brown
Kevin K. Brown
AFAryeh Fischer
Aryeh Fischer

3 January 2019 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
AFAryeh Fischer
Aryeh Fischer
MSMary E. Strek
Mary E. Strek
VCVincent Cottin
Vincent Cottin
PDPaul F. Dellaripa
Paul F. Dellaripa
EBElana J. Bernstein
Elana J. Bernstein
SDSeamas C. Donnelly
Seamas C. Donnelly

30 December 2021 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
TCTamera J Corte
Tamera J Corte
LLLisa Lancaster
Lisa Lancaster
JSJeffrey J Swigris
Jeffrey J Swigris
TMToby M Maher
Toby M Maher
JGJonathan G Goldin
Jonathan G Goldin
AFAryeh Fischer
Aryeh Fischer
Introduction: Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA1–6). Signalling via LPA1 appears to be fundamental in the pathogenesis of fibrotic diseases. BMS-986278, a second-generation LPA1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis: This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will consist of a 42-day screening period, a 26-week placebo-controlled treatment period, an optional 26-week active-treatment extension period, and a 28-day post-treatment follow-up. Patients in both the IPF (n=240) and PF-ILD (n=120) cohorts will be randomised 1:1:1 to receive 30 mg or 60 mg BMS-986278, or placebo, administered orally two times per day for 26 weeks in the placebo-controlled treatment period. The primary endpoint is rate of change in per cent predicted forced vital capacity from baseline to week 26 in the IPF cohort. Ethics and dissemination: This study will be conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and local ethical and legal requirements. Results will be reported in a peer-reviewed publication. Trial registration number: NCT04308681.

19 August 2019 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
AFAryeh Fischer
Aryeh Fischer
JDJörg Distler
Jörg Distler
Interstitial lung disease (ILD) is a common manifestation of systemic autoimmune diseases and a leading cause of death in these patients. A proportion of patients with autoimmune ILDs develop a progressive fibrosing form of ILD, characterized by increasing fibrosis on high-resolution computed tomography, worsening of lung function, and early mortality. Autoimmune disease–related ILDs have a variable clinical course and not all patients will require treatment, but all patients should be monitored for signs of progression. Apart from systemic sclerosis–associated ILD, the limited evidence to support the efficacy of immunosuppression as a treatment for ILDs is based mainly on small retrospective series and expert opinion. Non-clinical data suggest that there are commonalities in the mechanisms that drive progressive fibrosis in ILDs with an immunological trigger as in other forms of progressive fibrosing ILD. This suggests that nintedanib and pirfenidone, drugs known to slow disease progression in patients with idiopathic pulmonary fibrosis, may also slow the progression of ILD associated with systemic autoimmune diseases. In the SENSCIS® trial, nintedanib reduced the rate of ILD progression in patients with systemic sclerosis–associated ILD. The results of other large clinical trials will provide further insights into the role of anti-fibrotic therapies in the treatment of autoimmune disease–related ILDs.